Evidence map›Paper›PMID 34950982›Full record

ArticleAnalytical and bioanalytical chemistry2022

QCM-based assay designs for human serum albumin.

Wisnu Arfian A Sudjarwo, Mathias Thomas Dobler, Peter A Lieberzeit

Open access · hybridAbstract read
In one paragraph

Article in Analytical and bioanalytical chemistry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.8field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Wisnu Arfian A SudjarwoUniversity of Vienna, Faculty for Chemistry, Department of Physical Chemistry, Waehringer Strasse 42, 1090, Vienna, Austria.
Mathias Thomas DoblerUniversity of Vienna, Faculty for Chemistry, Department of Physical Chemistry, Waehringer Strasse 42, 1090, Vienna, Austria.
Peter A LieberzeitUniversity of Vienna, Faculty for Chemistry, Department of Physical Chemistry, Waehringer Strasse 42, 1090, Vienna, Austria. Peter.Lieberzeit@univie.ac.at.ORCID http://orcid.org/0000-0003-1596-0584
University of Vienna · AT

Funding

OeAD-GmbH Ernst Mach Grant - ASEA-UNINET scholarship progr
6 · The paper itself

Abstract

Solid-phase synthesis is an elegant way to create molecularly imprinted polymer nanoparticles (nano-MIPs) comprising a single binding site, i.e. mimics of antibodies. When using human serum albumin (HSA) as the template, one achieves nano-MIPs with 53 ± 19 nm diameter, while non-imprinted polymer nanoparticles (nano-NIPs) reach 191 ± 96 nm. Fluorescence assays lead to Stern-Volmer plots revealing selective binding to HSA with selectivity factors of 1.2 compared to bovine serum albumin (BSA), 1.9 for lysozyme, and 4.1 for pepsin. Direct quartz crystal microbalance (QCM) assays confirm these results: nano-MIPs bind to HSA immobilized on QCM surfaces. This opens the way for competitive QCM-based assays for HSA: adding HSA to nanoparticle solutions indeed reduces binding to the QCM surfaces in a concentration-dependent manner. They achieve a limit of detection (LoD) of 80 nM and a limit of quantification (LoQ) of 244 nM. Furthermore, the assay shows recovery rates around 100% for HSA even in the presence of competing analytes.

Indexed as

Molecular ImprintingQuartz Crystal Microbalance TechniquesHumansLimit of DetectionPolymersSerum Albumin, HumanPolymersSerum Albumin, HumanCompetitive assayHuman serum albuminMolecularly imprinted polymerNanoparticlesQuartz crystal microbalance

Identifiers

PMID34950982
PMCPMC8748353
OpenAlexW4200444346

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.